Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
Zacks Investment Research | Feb 20, 2020 09:44PM ET
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported adjusted earnings per share (EPS) of 75 cents in fourth-quarter 2019, which beat the Zacks Consensus Estimate of 68 cents by 10.3%. Moreover, the bottom line improved 13.6% year over year.
Revenues increased 3.3% year over year to $5.1 billion and beat the Zacks Consensus Estimate by 6.3%.
Segmental Details
In the fourth quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.
Health Care Services revenues improved 6% on a year-over-year basis and 3% at constant currency (cc). The improvement came on the back of growth in same market treatments, acquisitions, and increases in organic revenue per treatment. However, the effect of sold or closed clinics and decline courtesy of prior-year revenues from divested activities of Sound Physicians partially offset the improvement.
Health Care Products revenues climbed 10% year over year and 8% at cc. The upside can primarily be attributed to higher sales of home hemodialysis products, primarily as a result of the NxStage buyout and higher sales of dialyzers. Lower volume of sales of machines partially negated the upside.
Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.